AI in Healthcare M&A: Regulatory Risks, Due Diligence, and Deal Considerations

This CLE webinar will guide healthcare counsel on navigating AI issues in healthcare M&A. The panel will discuss the challenges for healthcare M&A involving AI, due diligence, and addressing risk in the deal documents. The panel will also address the regulatory risks and what considerations those involved in healthcare deals need to keep in mind. The panel will offer best practices for navigating the deal involving AI.

Healthcare M&A deals are under increasing scrutiny. Healthcare companies are able to create value by adding AI capabilities and often do this through mergers and acquisitions. AI is beneficial in the healthcare arena in a variety of ways from improved preventative care recommendations to more precise diagnoses and treatment.

However, healthcare companies looking to add AI capabilities through M&A need to weigh several deal considerations as well as regulatory risks. For example, a company needs to understand how the target company is protecting its data, including protected health information, when using AI, and whether the company has rights to the data it is using from an IP perspective as well as under HIPAA and other applicable state laws. The company will also need to be evaluated for compliance with FDA requirements.

Listen as our authoritative panel of healthcare attorneys examines the challenges for healthcare M&A involving AI. The panel will discuss due diligence and addressing risk in the deal documents. The panel will also address the regulatory risks and what considerations those involved in healthcare deals need to keep in mind. The panel will offer best practices for navigating the deal involving AI.